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Abstract 
Patients with bloodstream infections (BSI) are associated with high mortality rates. Due to tigecycline has shown 
excellent in vitro activity against most pathogens, tigecycline is selected as one of the candidate drugs for the 
treatment of multidrug-resistant organisms infections. The purpose of this study was to evaluate the effectiveness 
and safety of the use of tigecycline for the treatment of patients with BSI. The PubMed and Embase databases were 
systematically searched, to identify published studies, and we searched clinical trial registries to identify completed 
unpublished studies, the results of which were obtained through the manufacturer. The primary outcome was mortal-
ity, and the secondary outcomes were the rate of clinical cure and microbiological success. 24 controlled studies were 
included in this systematic review. All-cause mortality was lower with tigecycline than with control antibiotic agents, 
but the difference was not significant (OR 0.85, [95% confidence interval (CI) 0.31–2.33; P = 0.745]). Clinical cure was 
significantly higher with tigecycline groups (OR 1.76, [95% CI 1.26–2.45; P = 0.001]). Eradication efficiency did not dif-
fer between tigecycline and control regimens, but the sample size for these comparisons was small. Subgroup analy-
ses showed good clinical cure result in bacteremia patients with CAP. Tigecycline monotherapy was associated with a 
OR of 2.73 (95% CI 1.53–4.87) for mortality compared with tigecycline combination therapy (6 studies; 250 patients), 
without heterogeneity. Five studies reporting on 398 patients with Klebsiella pneumoniae carbapenemase-producing 
K. pneumoniae BSI showed significantly lower mortality in the tigecycline arm than in the control arm. The combined 
treatment with tigecycline may be considered the optimal option for severely ill patients with BSI.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Bloodstream infections (BSI) are potentially life-threat-
ening diseases. BSI was defined as at least 1 positive 
blood culture for a recognized pathogen and clinical 
symptoms consistent with bacteraemia. They can cause 
serious secondary infections, such as infective endocar-
ditis and osteomyelitis, and may result in severe sepsis. 
Meanwhile, BSI due to multidrug-resistant (MDR) organ-
isms has been associated with multiple poor outcomes, 
including increased length of hospital stay, health care 
costs and a high rate of morbidity and mortality.
Tigecycline is a glycylcycline with a broad spectrum 
of antibacterial activity. The emergence of MDR strains 
infections has been extensively observed worldwide and 
has become a priority issue over past decade. Tigecycline 
is a useful alternative to face the challenges of many MDR 
organisms. Tigecycline has a large volume of distribution 
of 7–10 l/kg [1], penetrating well into different tissues, it 
has been approved for the treatment of complicated skin 
and soft-structure infections (cSSSI), complicated intra-
abdominal infections (cIAI), and community-acquired 
bacterial pneumonia (CAP). Tigecycline is not indicated 
for treatment of diabetic foot infection or for hospital-
acquired or ventilator-associated pneumonia [2]. The use 
of tigecycline in bacteremia is controversial because of its 
low serum levels with standard dosing [3].
Attention should be paid by clinicians, because tige-
cycline was associated with higher mortality than 
comparator antibiotics [4–6]. However, a recent meta-
analysis showed that the drug was not associated with 
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significantly higher mortality than comparator antibiot-
ics and was as effective as comparators when the analy-
sis was restricted to patients who received tigecycline for 
approved indications [7]. A prospective study demon-
strates that tigecycline plus prolonged infusion standard-
dose imipenem/cilastatin, showed good clinical efficacy 
on VAP patients with XDR-Ab VAP bacteremia [8]. The 
increased mortality associated with tigecycline is not yet 
well understood in the treatment of BSI. Therefore, we 
systemically searched and analysed the current available 
evidence to assess clinical effectiveness of tigecycline for 
the treatment of BSI.
Methods
Literature search
Relevant studies were identified through PubMed, 
Embase and hand-searched from inception until Octo-
ber 2016.The search terms were:“(tigecycline OR TGC 
OR tygacil) and (bacteraemia OR bacteremia OR blood-
stream infection OR sepsis OR septicaemia)”. No lan-
guage restrictions were applied.
Study selection
Any article providing the clinical outcomes of patients 
treated for bloodstream infections caused by any etio-
logical agent was considered eligible for inclusion in 
the review. Prospective and retrospective observational 
cohort studies examining the association between tige-
cycline use (on hospital admission or previous users) 
and the outcomes of bacteremic patients were included. 
The outcome of interest was overall hospital mortality at 
the longest follow-up at each single study. Case reports 
and case series including fewer than 10 infected patients 
treated with tigecycline were excluded from the review.
Data extraction
The extracted data consisted of the main characteristics 
of a study (first-author name, year of publication, coun-
try, study period, and design), main characteristics and 
underlying diseases of the study population, number of 
patients with infections BSI, the causative pathogen(s), 
sites of infections, and antibiotic treatment (combination 
therapy or monotherapy). Clinical outcomes (mortality, 
treatment failure) of patients in each treatment group 
were recorded as well.
Statistical analysis
We chose mortality as the primary outcome, because of 
the high mortality rates among patients with BSI, while 
the secondary outcomes were: clinical response, micro-
biological response, adverse effects, and emergence of 
resistance. Microbiological response was defined as suc-
cessful when eradication or sterile culture results were 
obtained during or after the antibiotic therapy. Because 
there are no standard criteria to assess clinical response 
and adverse events, we accepted the criteria as reported 
in each study.
All statistical analyses were performed using the com-
prehensive meta-analysis V2.2 (BioStat, Englewood, NJ). 
Among the controlled studies, the between-study het-
erogeneity was assessed using the  I2 test, whereby  I2 val-
ues >50% were defined as indicating heterogeneity. Either 
fixed-effects (Mantel–Haenszel method) or random-
effects (DerSimonian and Laird method) models were 
used, depending on the heterogeneity result. If no het-
erogeneity was found, meta-analysis was done using the 
Mantel–Haenszel fixed-effects model. Binary outcomes 
from controlled studies were expressed as odds ratios 
(OR) with their 95% confidence intervals (CI), and con-
tinuous outcomes were expressed as the mean difference 
between 2 groups. Egger regression, as well as the Begg 
methods, was used to evaluate publication bias. All P val-
ues were two-tailed, and a P value of ≤0.05 was consid-
ered statistically significant. Some statistical analysis was 
performed by using the SPSS statistical software (version 
19; SPSS Inc., Chicago, IL). Categorical variables were 
evaluated by using the χ2 test or 2-tailed Fisher’s exact 
test, as appropriate. Subgroup analyses for mortality 
and clinical cure were planned for bacteraemic patients. 
Comparisons were subcategorized by the type of infec-
tion. A funnel plot was used to assess small-study effects.
Results
Literature search results
1540 potential articles were identified; 56 case reports 
and clinical series including less than 10 infected patients 
were excluded; 41 duplicates and 18 single-arm studies 
were excluded; 22 studies were ruled out because they did 
not present clear treatment regimens or detailed clinical 
outcomes; 24 articles were excluded due to few patients 
in each group. Ultimately 24 studies met the inclusion 
criteria, 24 controlled studies (1961 patients) included in 
this systematic review.
Study characteristics
The features of the 24 trials are described in Table 1. Five 
of them were prospective cohort studies, 7 were retro-
spective studies. All of the included controlled studies 
had an NOS score >3. Most patients in the included stud-
ies were critically ill, with most of them in ICU.
Mortality
As shown in Fig.  1, no significant difference was noted 
when tigecycline was compared with control groups in 
terms of all-cause mortality (14 studies; 1502 patients) 
[OR 0.841, 95% confidence interval (CI) 0.517–1.367; 
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P  =  0.485]. Because statistical heterogeneity existed 
among studies  (X2  =  32.76, df  =  13, (P  =  0.002), 
 I2  =  60.3%), a random-effects model of analysis was 
used. No publication bias was detected by Egger regres-
sion (t = −0.39; df = 12.0; P = 0.701) or Begg (z = 0.55; 
df = 12.0; P = 0.584).
Table 2 shows the subgroup analysis of the controlled 
studies. A significant difference was observed between 
the tigecycline monotherapy therapy group and the 
tigecycline combination therapy group in terms of 
mortality (6 studies; 250 patients) (OR 2.733, [95% CI 
1.533–4.873; P = 0.001];  I2 = 8.7%). A significantly higher 
mortality was noted in the monotherapy group than in 
the combination therapy group in cases of blood stream 
infection. The mortality in the combination of tigecycline 
plus colistin based group was not significantly lower than 
that in the other antibiotics combination group (OR 0.68, 
[95% CI 0.407–1.135; P = 0.14];  I2 = 0.0%).
Fig. 1 Mortality with tigecycline versus other antibiotics therapy
Table 2 Subgroup analysis of  overall mortality with  tigecycline versus  other antibiotics for  treatment of  bloodstram 
infections in controlled studies
CI, confidence interval; OR, odds ratio
Variables Studies, no. 
(patients, no.)
Mortality of tigecycline compared 
with control OR (95% CI); P
Heterogeneity of studies
Monotherapy vs combination 6 (250) 2.733 (1.533–4.873); 0.001 X2 = 5.47, df = 5, (P = 0.361),  I2 = 8.7%
Tigecycline plus polymyxins based vs 
other antibiotics combination
5 (289) 0.680 (0.407–1.135); 0.140 X2 = 2.88, df = 4, (P = 0.578),  I2 = 0.0%
Kp BSI 6 (466) 0.678 (0.457–1.006); 0.054 X2 = 3.95, df = 5, (P = 0.556),  I2 = 0.0%
KPC-Kp BSI 5 (398) 0.636 (0.417–0.971); 0.036 X2 = 3.31, df = 4, (P = 0.507),  I2 = 0.0%
Acinetobacter BSI 3 (221) 0.967 (0.096–9.759); 0.978 X2 = 23.76, df = 2, (P = 0.001),  I2 = 91.6%
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In the patients infected with Klebsiella pneumoniae 
(Kp) BSI, tigecycline seemed to have a lower mortal-
ity than comparator drugs, but the difference was not 
significant (OR 0.678, [95% CI 0.457–1.006; P =  0.054]; 
 I2  =  0.0%; [P  =  0.556]). Five studies (398 patients) 
reported data on carbapenemase-producing Kp BSI, and 
a significant difference with respect to overall mortality 
was observed between the tigecycline therapy group and 
the controls (OR 0.636, [95% CI 0.417–0.971; P = 0.036]; 
 I2  =  0.0%; [P  =  0.507]). Three controlled studies (221 
patients) reported Acinetobacter BSI, no difference was 
seen between patients who received tigecycline as ther-
apy and others in mortality (OR 0.967, [95% CI 0.096–
0.759; P = 0.978];  I2 = 91.6%; [P = 0.001]).
Clinical cure
There was a significant differences were observed 
between the tigecycline and control groups in this regard 
(OR 1.76, [95% CI 1.26–2.45; P  =  0.001];  I2  =  29.2%; 
[P = 0.159]; Fig. 2). Clinical cure was significantly higher 
in the tigecycline population. In the subgroup analysis, 
for analysis by type of infection, without statistical sig-
nificance was found in patients with cIAI (OR 0.97, [95% 
CI 0.52–1.80; P  =  0.919];  I2  =  0.0%; [P  =  0.953]) and 
cSSSI (OR 0.71, [95% CI 0.26–1.90; P = 0.494];  I2 = 0.0%; 
[P  =  0.821]), but in trials assessing patients with CAP, 
for the rate of clinical cure, the efficacy of tigecycline 
was better than that of comparator regimens (OR 2.44, 
[95% CI 1.20–4.94; P = 0.013];  I2 = 0.0%; [P = 0.821]). As 
shown in Fig. 2.
Microbiological response
As shown in Fig. 2, tigecycline group did not differ sig-
nificantly compared with the comparators in the rate of 
microbiological success (OR 2.07, [95% CI 0.56–7.70; 
P = 0.279];  I2 = 0.0%; [P = 0.854]) (Fig. 2).
Adverse effects
There were not sufficiently effective data to be recoded, 
so that the common adverse effects of tigecycline (nau-
sea, vomiting, and diarrhea) could not be extracted in any 
of the studies.
Discussion
We conducted this systematic review and meta-analysis 
to investigate the effectiveness and safety of tigecycline 
for the treatment of BSI. Numerous studies have estab-
lished bacteremia as a marker of severe infection and a 
Fig. 2 The efficacy of tigecycline, as compared with other antibiotics, in treating infections caused by BSI
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risk for adverse outcomes in multiple treatment settings 
[9, 10], but there were some positive elements about the 
treatment of BSI with tigecycline.
To our knowledge, this was the first systematic review 
to assess the efficacy of tigecycline in treating BSI. 
Although all-cause mortality was lower with tigecycline 
than with the control regimens, the difference was not 
significant. Tigecycline seemed to be better than levo-
floxacin for treatment of community-acquired pneumo-
nia, and worse than control regimens for cIAI and cSSSI, 
but these differences were not significant. However, 
drug safety guidelines published by the FDA refer to an 
increased mortality risk associated with intravenous tige-
cycline compared with other drugs used to treat serious 
infections (risk difference  =  0.6%, 95% CI 0.1–1.2) [2]. 
This result has been confirmed by a study that associ-
ated the increased risk mortality with resistant patho-
gens, hospital-acquired pneumonia, and increased age 
of patients [11]. However the type of serious infections 
didn’t include BSI. We used the same effect metric to 
assess our results, and noted that the risk difference of 
all-cause mortality was not significant (−3.5%, 95% CI 
−13 to −6;  I2 = 85.4%, P = 0.001).
Although the overall mortality did not differ between 
tigecycline and the control groups, subgroup analysis 
found the mortality was significantly lower in the tigecy-
cline combination group than in the tigecycline mono-
therapy therapy group. Tigecycline in combination with 
colistin, carbapenem in combination with colistin, and 
tigecycline in combination with gentamicin were the 
commonly administered antibiotic treatment regimens 
among the included studies and might result in lower 
mortality than other combinations of antibiotics. The 
most common combination was tigecycline with colistin 
in tigecycline combination therapy group, yet this data 
did not necessarily predict tigecycline plus polymyxins 
based therapy was significantly better than other antibi-
otics combination therapy. For the patients with KPC-Kp 
BSI, antibiotic therapy with tigecycline was associated 
with lower mortality.
With regard to clinical response, the evidence that we 
could compile from studies was that tigecycline therapy 
may have no clinical advantage over comparator therapy, 
but may result in better clinical cure in treatment of CAP 
presenting with bacteremia.
Tigecycline had good eradication ability for most 
pathogens recorded at baseline, as a novel glycylcy-
cline antibiotic, it has a broad spectrum of antimicro-
bial activity, ranging from aerobic to anaerobic bacteria, 
and gram-positive, gram-negative (exceptions of Pseu-
domonas aeruginosa and Proteus mirabilis), and atypi-
cal organisms [12]. Eradication was better than with 
control regimens in all cases, although no significant 
difference was found when tigecycline was compared 
with the comparators.
Previous studies have shown that the most common 
adverse effects of tigecycline had increased incidence in 
the tigecycline group, such as nausea, vomiting, and diar-
rhea [13, 14]. According to a recently published review, 
tigecycline induces acute pancreatitis, indicating that 
surveillance for adverse events from the digestive system 
is needed during treatment [15]. But lack of data from all 
trials results can not be obtained about adverse events 
outcomes in our meta-analysis.
Small non-comparative series have reported relatively 
poor clinical and microbiological outcomes with tigecy-
cline for tigecycline-susceptible CR-Ab bacteremia [16–
18]. The high severity of illness and the notable delays 
in initiation of effective antimicrobial therapy could also 
explain these results. In a pooled, retrospective data anal-
ysis of phase 3 clinical trials, 91 patients being treated 
with tigecycline had secondary bacteremia detected, tige-
cycline appeared safe and well tolerated in the treatment 
of secondary bacteremia associated with cSSSI, cIAI, 
and CAP; cure rates were similar to comparative stand-
ard therapies [19]. Recently, a high-dose regimen (load-
ing dose 200 mg followed by 100 mg every 12 h) has been 
successfully and safely used in critically ill patients with 
severe infections due to multi drug resistant bacteria 
although the number of primary bacteremia was anecdo-
tal [20].
Several potential limitations should be taken into con-
sideration when interpreting the present results. Firstly, 
the number of subjects included was not large enough. 
We would have preferred to contact researchers directly 
for missing data, but this approach was not attempted 
because of time constraints. Secondly, in some subgroup 
analyses, the sample size was small, which may have 
reduced the power of the statistical analysis. Another 
important issue is that the administrations of the antibi-
otics differed among the studies with regard to the dura-
tion of infusion or the total daily dose. Thirdly, due to the 
included studies did not provide relevant data, we were 
unable to assess the impact of tigecycline on adverse drug 
reactions. Accordingly, these differences might influence 
the clinical outcomes. Last, the matter of the emergence 
of resistance during therapy was not raised by any of the 
included studies.
In conclusion, based on a review of published cases, 
tigecycline appears to have produced some favourable 
clinical and microbiological outcomes in patients with 
BSI, even when used as monotherapy. This research 
was needed to clarify whether tigecycline was suit-
able for treatment such infections when other antibiot-
ics fail, especially because indications for increased risk 
of all-cause mortality have been reported in patients 
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treated with this drug. The FDA has recently reported 
an increased risk of death when intravenous tigecycline 
is used for FDA approved purposes [21], which may be 
explained by a worsening infection or potential complica-
tions [11].
The available evidence suggests that combination anti-
biotic treatment may offer a comparative advantage over 
monotherapy with regard to the mortality of critically ill 
patients with severe infections due to BSI. The number 
of currently available appropriate antimicrobial agents is 
limited, combination therapy with tigecycline, it could 
be a fine option for the treatment of BSI, especially in 
patients with KPC-Kp BSI.
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